PHRR.F Stock Overview
PharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PharmaTher Holdings Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.21 |
| 52 Week High | CA$0.32 |
| 52 Week Low | CA$0.062 |
| Beta | 3.27 |
| 1 Month Change | -2.84% |
| 3 Month Change | 9.95% |
| 1 Year Change | 108.69% |
| 3 Year Change | 17.82% |
| 5 Year Change | n/a |
| Change since IPO | 16.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHRR.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 7.7% | 1.6% | 3.3% |
| 1Y | 108.7% | 12.6% | 25.8% |
Return vs Industry: PHRR.F exceeded the US Pharmaceuticals industry which returned 12.6% over the past year.
Return vs Market: PHRR.F exceeded the US Market which returned 25.8% over the past year.
Price Volatility
| PHRR.F volatility | |
|---|---|
| PHRR.F Average Weekly Movement | 20.9% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PHRR.F's share price has been volatile over the past 3 months.
Volatility Over Time: PHRR.F's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | n/a | Fabio Chianelli | www.pharmather.com |
PharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. The company’s product pipeline includes KETARX, a hydrochloride injection for the treatment of Parkinson’s disease, Amyotrophic Lateral Sclerosis, complex regional pain and Rett syndrome, and anesthesia and procedural sedation, as well as Ischemia reperfusion injury. It also develops KETARX, a microneedle patch, for mental health, neurological, and pain disorders; and KETARX On-body pump for the maintenance of general anesthesia for diagnostic and surgical procedures.
PharmaTher Holdings Ltd. Fundamentals Summary
| PHRR.F fundamental statistics | |
|---|---|
| Market cap | US$17.08m |
| Earnings (TTM) | -US$3.17m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.3x
P/E RatioIs PHRR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHRR.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$4.35m |
| Earnings | -CA$4.35m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.049 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PHRR.F perform over the long term?
See historical performance and comparison